KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points.

Neal D Shore, Ugo De Giorgi, Ronald F Tutrone, James L Bailen, Erik P M Roos, Ján Kliment, Gavin Marx, Lawrence I Karsh, Miguel Ramirez-Backhaus, Edward M Uchio, Stéphane Supiot, Yiyun Tang, Brad Rosbrook, Gabriel P Haas, Matt Rosales, Fabian Zohren, Jamal Tarazi, Stephen J Freedland

J Urol 215(4) 396-407

PMID41349040
PMCIDPMC12978717
DOI10.1097/JU.0000000000004879
发表日期2025-12-05
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

PURPOSE: Primary analysis of the phase 3 EMBARK trial reported efficacy and safety outcomes for enzalutamide monotherapy in patients with high-risk biochemical recurrence. Here, we report secondary end points for enzalutamide monotherapy vs leuprolide alone. MATERIALS AND METHODS: Patients were randomized (1:1:1) to enzalutamide plus leuprolide, leuprolide alone, or enzalutamide monotherapy. Overall survival was a key secondary end point; non-key secondary end points were time to: distant metastasis, symptomatic progression, first symptomatic skeletal event, and resumption of any hormonal therapy. Sexual health was assessed using the Quality of Life Questionnaire-Prostate 25. Time-to-event end points were summarized using Kaplan-Meier methods with nominal P values. RESULTS: Five-year probability rates (95% CI) for enzalutamide monotherapy vs leuprolide alone were: overall survival, 89.5% (85.6-92.4) vs 87.2% (83.0-90.4); time to remaining free from distant metastasis, 86.8% (82.3-90.2) vs 81.5% (76.3-85.7); symptomatic progression, 66.6% (61.2-71.4) vs 53.3% (47.6-58.6); and first symptomatic skeletal event, 95.8% (92.9-97.6) vs 91.5% (87.8-94.1). After treatment suspension, the 5-year probability rate (95% CI) of remaining free from resumption of any hormonal therapy for leuprolide alone vs enzalutamide monotherapy was 7.8% (4.4-12.3) vs 5.6% (3.3-8.8). Sexual health was better preserved in patients treated with enzalutamide monotherapy than leuprolide alone (HR 0.76; 95% CI: 0.62-0.94; P = .008). After discontinuation, most patients were subsequently treated with hormonal therapies in both groups. CONCLUSIONS: Secondary end point results support enzalutamide monotherapy as a potential option to improve efficacy and preserve sexual health vs leuprolide alone for patients with high-risk biochemical recurrence. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02319837.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Figure 2

Figure 2. Kaplan-Meier estimates of (A) overall survival, (B) time to distant metastasis, (C) time to symptomatic progression, (D) time to resumption of any hormonal therapy after treatment suspension, and (E) time to first confirmed deterioration of sexual function (intention-to-treat population). The data cutoff was January 31, 2023. Treatment effects by HR and 95% CI were estimated by stratified Cox regression models, as described previously. Times to distant metastasis, symptomatic progression, resumption of any hormonal therapy, and confirmed deterioration of sexual activity are presented in Supplementary Table 1 ( https://www.jurology.com ). Kaplan-Meier curves were truncated when there were zero patients at risk in both groups.

D

time to resumption of any hormonal therapy

Figure 2 · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal
查看结果
E

time to first confirmed deterioration of sexual function

Figure 2 · Panel E

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel E 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

captionless-figureGraphical abstract
非 KM Figure
Figure.Figure. Study overview. BCR indicates biochemical recurrence; nmCSPC, nonmetastatic castration-sensitive prostate cancer.
非 KM Figure
Figure 1Figure 1. Trial profile. Copyright © (2023) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
非 KM Figure
Figure 3Figure 3. Metastasis-free survival for prespecified subgroups from enzalutamide monotherapy vs leuprolide alone (intention-to-treat population). The data cutoff was January 31, 2023. Treatment effects by HR and 95% CI were estimated by stratified Cox regression models, as described previously. According to the statistical analysis plan, the prespecified sample size requirement was at least 10 events in a subgroup to allow meaningful comparison. ECOG indicates Eastern Cooperative Oncology Group; PSADT, PSA doubling time.
非 KM Figure